Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms

Can J Psychiatry. 1994 Mar;39(2):74-84. doi: 10.1177/070674379403900203.


Most patients on neuroleptic therapy experience extrapyramidal symptoms in one form or another during treatment. While the risk of extrapyramidal symptoms appears diminished with the newer and "atypical" neuroleptics (for example, risperidone, remoxipride, clozapine), it is not eliminated. It is essential that the treating clinician monitor for such side effects since if they are left untreated they can be an ongoing source of discomfort to the patient and may affect compliance with therapy. Antiparkinsonian medication represents the mainstay of treatment for neuroleptic-induced extrapyramidal symptoms. Their clinical use is reviewed here with reference to mode of action, indications, choice, side-effects and precautions.

Publication types

  • Review

MeSH terms

  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / therapeutic use*
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Basal Ganglia Diseases / chemically induced*
  • Basal Ganglia Diseases / drug therapy
  • Dyskinesia, Drug-Induced / drug therapy*
  • Humans
  • Parkinson Disease, Secondary / chemically induced*
  • Parkinson Disease, Secondary / drug therapy
  • Treatment Outcome


  • Antiparkinson Agents
  • Antipsychotic Agents